Polaris Group announced the submission to TFDA of phase 2a clinical protocol treating non-Alcohol steatohepatitis (NASH) with ADI-PEG 20, a first-in-class arginine deprivation therapy. The trial is designed as a randomized, double-blind, multi-center study for the treatment of NASH.